drugset / Trial / NCT00719706
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this 15-week clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than placebo as an augmentation treatment in bipolar depressed patients who display an incomplete response to conventional treatments.
Timeline
- Start
- 2008-08
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetylcarnitine | Small molecule | 1000 mg | — |
| Comparator | Acetylcarnitine | Small molecule | 3000 mg | — |
| Comparator | alpha-lipoic acid | Small molecule | 600 mg | — |
| Comparator | alpha-lipoic acid | Small molecule | 1800 mg | — |